Aragen Life Sciences Files DRHP with SEBI for ₹800 Crore IPO

Beyond the IPO Size: 7 IPO-Readiness Lessons from Aragen Life Sciences' DRHP


Hyderabad-based contract research, development and manufacturing organisation (CRDMO) Aragen Life Sciences has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for a proposed initial public offering.


The issue comprises a fresh issue of shares aggregating up to ₹800 crore and an offer for sale of up to 2.73 crore equity shares (27,329,192 shares) of face value ₹10 each by existing shareholders. Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities and JM Financial are the book running lead managers to the issue.


Aragen has stated that proceeds from the fresh issue will go towards repayment or pre-payment of borrowings, capital expenditure for new equipment and machinery at its Hyderabad facilities, capital expenditure by its subsidiary Aragen Biologics at its Bengaluru facility, and general corporate purposes to support its next phase of growth.


Incorporated in 2000, Aragen positions itself as one of the largest CRDMOs among assessed Indian peers by the number of solutions offered across the drug development value chain, and among the top three Indian CRDMOs by operating revenue, operating in a global CRDMO market it estimates at $171 billion in FY26. The company reported that revenue from operations, profit for the year, adjusted EBITDA and adjusted profit for the year grew at compounded annual rates of roughly 14.6%, 26.9%, 15.6% and 29.9% respectively, reaching ₹2,178.39 crore, ₹257.64 crore, ₹593.77 crore and ₹283.99 crore in FY26, with ROCE of 18.18% and ROE of 11.96%.



Key Highlights

• Fresh issue of up to ₹800 crore plus an offer for sale of up to 2.73 crore shares
  
  

• Fund utilisation spans debt repayment, capex at Hyderabad and Bengaluru facilities, and general corporate purposes
  
  

• Four book running lead managers appointed for the issue
  
  

• Multi-year track record of revenue and profit growth disclosed in the draft papers, alongside ROCE and ROE metrics
  
  

• A CRDMO business model built on a large, diversified global customer base
  
  

• Filing comes amid a broader wave of DRHP filings and IPO activity in India through August 2026
  
  

Body: What the Aragen DRHP Signals About IPO Readiness

A DRHP is far more than a fundraising announcement. It is a company's first formal, public account of its business, finances, risks and governance to a regulator and to prospective investors. For promoters and finance teams preparing for a listing, the Aragen filing offers a useful lens on what "IPO readiness" actually involves in practice. Here are seven areas worth examining closely.


1. A clearly stated purpose for the funds
Aragen has laid out specific, categorised uses for its fresh issue proceeds — debt repayment, capex at named facilities, and general corporate purposes. Regulators and investors expect this level of specificity. A vague or generic "for business purposes" statement raises questions during due diligence and can slow the review process. Promoters preparing for an IPO should be able to map each rupee of intended proceeds to a defined business outcome well before filing.


2. A visible debt position and repayment plan
Allocating a portion of proceeds to repayment or pre-payment of borrowings signals that the company has taken stock of its balance sheet ahead of going public. IPO readiness includes a clear-eyed view of existing debt levels, covenants and repayment obligations, and being able to explain how the offering improves the capital structure.


3. Capex tied to specific, named facilities
Aragen's plans for its Hyderabad facilities and its subsidiary's Bengaluru facility are concrete rather than aspirational. Capex plans that name locations, purposes and expected outcomes are easier for investors to evaluate than broad statements about "expansion." This level of detail also reflects internal planning discipline that regulators look for.


4. A demonstrable, multi-year operating track record
The draft papers disclose growth in revenue, profit, adjusted EBITDA and adjusted profit over several years, along with capital efficiency metrics such as ROCE and ROE. Consistent, verifiable historical performance — not just a single strong year — is central to how the market assesses an issuer's credibility. Companies preparing to file should ensure their financial history is audit-ready and consistent across the disclosure period required.


5. Customer concentration and business-model disclosure
A CRDMO business depends on relationships with global pharmaceutical and biotech clients. How a company discloses its customer base, dependency on top clients, and diversification across geographies and client segments has a direct bearing on how risk factors are perceived. IPO aspirants should assess and disclose customer concentration honestly rather than treat it as a footnote.


6. Board oversight and governance framework
Public market investors weigh governance structures alongside financial numbers. A documented framework for board oversight, sustainability commitments and responsible business conduct signals institutional maturity. Promoters should treat governance readiness — board composition, committees, policies — as a workstream that begins well ahead of the DRHP filing, not something assembled at the last stage.


7. Risk factor and disclosure quality
A DRHP's risk factors section is closely scrutinised by regulators and investors alike. The depth, honesty and specificity of these disclosures — covering everything from market dependence to regulatory exposure — often determines how smoothly a filing moves through SEBI's review. Companies should approach this section as a genuine risk assessment exercise, not a compliance formality.


Taken together, these areas illustrate that IPO readiness is not defined by issue size alone. It is built through disciplined financial reporting, a clear capital allocation rationale, sound governance and transparent disclosure — well before a company approaches the market.



Conclusion

The Aragen Life Sciences DRHP filing is a useful reference point for promoters, CFOs and finance heads evaluating their own readiness for a mainboard listing. Beyond the headline ₹800 crore fresh issue, the filing reflects the kind of preparation — clear fund utilisation, visible debt management, facility-specific capex planning, a demonstrable track record, and governance discipline — that regulators and investors look for at the DRHP stage. Companies planning a similar journey would do well to assess their own readiness across these dimensions well in advance of filing.


FinMen Advisors works with promoters and finance teams to strengthen IPO readiness and rating preparedness across these very dimensions — from financial documentation to disclosure quality. To understand your rating readiness or prepare before approaching lenders and investors, book an Initial Assessment with our team.



Source: Business Today, "Aragen Life Sciences filed DRHP with SEBI to launch its IPO; check all key details," August 27, 2026.



Disclaimer

This article is based on information disclosed in Aragen Life Sciences' Draft Red Herring Prospectus filed with SEBI and publicly reported news coverage as of the date of publication. It is intended for general informational and educational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or an offer or solicitation in connection with the proposed IPO. The DRHP is a draft document and remains subject to review by SEBI; details may change before the final prospectus is filed. Readers are advised to consult the final offer documents and a qualified financial or investment advisor before making any investment decision. FinMen Advisors Private Limited is an advisory firm and is not a SEBI-registered credit rating agency, investment advisor, or merchant banker to this issue.